GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    ChemInform Abstract: Development of Delivery System of Bisphosphonates for the Treatment of Osteoporosis
    Wiley ; 2011
    In:  ChemInform Vol. 42, No. 4 ( 2011-01-25), p. no-no
    Details
    In: ChemInform, Wiley, Vol. 42, No. 4 ( 2011-01-25), p. no-no
    Type of Medium: Online Resource
    ISSN: 0931-7597
    URL: Issue
    URL: Article
    DOI: 10.1002/chin.v42.4
    DOI: 10.1002/chin.201104273
    Language: English
    Publisher: Wiley
    Publication Date: 2011
    detail.hit.zdb_id: 2110203-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Intranasal rifampicin for Alzheimer's disease prevention
    Wiley ; 2018
    In:  Alzheimer's & Dementia: Translational Research & Clinical Interventions Vol. 4, No. 1 ( 2018-01), p. 304-313
    Details
    In: Alzheimer's & Dementia: Translational Research & Clinical Interventions, Wiley, Vol. 4, No. 1 ( 2018-01), p. 304-313
    Abstract: Oral rifampicin has been shown to significantly reduce amyloid β (Aβ) and tau pathologies in mice. However, it shows occasional adverse effects such as liver injury in humans, making its use difficult for a long period. Methods To explore safer rifampicin treatment, APP OSK mice, a model of Alzheimer's disease, were treated with rifampicin for 1 month via oral, intranasal, and subcutaneous administration, and its therapeutic efficacy and safety were compared. Results Intranasal or subcutaneous administration of rifampicin improved memory more effectively than oral administration. The improvement of memory was accompanied with the reduction of neuropathologies, including Aβ oligomer accumulation, tau abnormal phosphorylation, and synapse loss. Serum levels of a liver enzyme significantly rose only by oral administration. Pharmacokinetic study revealed that the level of rifampicin in the brain was highest with intranasal administration. Discussion Considering its easiness and noninvasiveness, intranasal administration would be the best way for long‐term dosing of rifampicin.
    Type of Medium: Online Resource
    ISSN: 2352-8737 , 2352-8737
    URL: Article
    DOI: 10.1016/j.trci.2018.06.012
    Language: English
    Publisher: Wiley
    Publication Date: 2018
    detail.hit.zdb_id: 2832891-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Development of a novel transdermal patch of alendronate, a nitrogen‐containing bisphosphonate, for the treatment of osteoporosis
    Wiley ; 2010
    In:  Journal of Bone and Mineral Research Vol. 25, No. 12 ( 2010-12), p. 2582-2591
    Details
    In: Journal of Bone and Mineral Research, Wiley, Vol. 25, No. 12 ( 2010-12), p. 2582-2591
    Abstract: Bisphosphonates are widely used for the treatment and prevention of bone diseases, including Paget disease, hypercalcemia of malignancy, and postmenopausal osteoporosis. In this study, we developed a novel transdermal patch of alendronate, a nitrogen‐containing bisphosphonate, for the treatment of bone diseases. The maximum permeation fluxes of alendronate through rat and human skin after application of this patch were 1.9 and 0.3 µg/cm 2 per hour, respectively. The bioavailability (BA) of alendronate in rats was approximately 8.3% after the application of alendronate patch and approximately 1.7% after oral administration. These results indicated that the transdermal permeation of alendronate using this patch system was sufficient for the treatment of bone diseases. The plasma calcium level was effectively reduced after application of the alendronate patch in 1α‐hydroxyvitamin D 3 –induced hypercalcemia model rats. The alendronate patch also effectively suppressed the decrease in bone mass in model rats with osteoporosis. Modest alendronate‐induced erythema of rat skin was observed after application of the alendronate patch. Incorporation of butylhydroxytoluene in the alendronate patch almost completely suppressed this alendronate‐induced skin damage while maintaining the transdermal permeation and pharmacologic effects of alendronate. These findings indicate that our novel transdermal delivery system for alendronate is a promising approach to improve compliance and quality of life of patients in the treatment of bone diseases. © 2010 American Society for Bone and Mineral Research.
    Type of Medium: Online Resource
    ISSN: 0884-0431 , 1523-4681
    URL: Issue
    URL: Article
    DOI: 10.1002/jbmr.v25:12
    DOI: 10.1002/jbmr.147
    RVK:
    XA 52230
    Language: English
    Publisher: Wiley
    Publication Date: 2010
    detail.hit.zdb_id: 2008867-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Absorption and Metabolism of Antioxidative Polyphenolic Compounds in Red Wine
    Wiley ; 2002
    In:  Annals of the New York Academy of Sciences Vol. 957, No. 1 ( 2002-05), p. 325-328
    Details
    In: Annals of the New York Academy of Sciences, Wiley, Vol. 957, No. 1 ( 2002-05), p. 325-328
    Abstract: A bstract : We have shown that drinking red wine reduces oxidation of LDL. This reduction in oxidation has been attributed to the polyphenolic compounds in red wine, but the mechanisms of absorption and metabolism of these compounds has been unclear. We therefore investigated the absorption and metabolism of polyphenols using rats to identify their active forms in biological fluids. We also investigated the effect of tartaric acid (TA), a major organic acid in wine, on the absorption of polyphenols. Our results suggested that low molecular weight polyphenols are absorbed in the intestine and metabolized to their glucuronide conjugates, which exhibit antioxidative activity in plasma, and that TA can enhance the bioavailability of wine polyphenols.
    Type of Medium: Online Resource
    ISSN: 0077-8923 , 1749-6632
    URL: Issue
    URL: Article
    DOI: 10.1111/nyas.2002.957.issue-1
    DOI: 10.1111/j.1749-6632.2002.tb02934.x
    RVK:
    TD 7650
    Language: English
    Publisher: Wiley
    Publication Date: 2002
    detail.hit.zdb_id: 2834079-6
    detail.hit.zdb_id: 211003-9
    detail.hit.zdb_id: 2071584-5
    SSG: 11
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Amyloid beta cleavage by ANA‐TA9, a synthetic peptide from the ANA/BTG3 Box A region
    Wiley ; 2021
    In:  Alzheimer's & Dementia: Translational Research & Clinical Interventions Vol. 7, No. 1 ( 2021-01)
    Details
    In: Alzheimer's & Dementia: Translational Research & Clinical Interventions, Wiley, Vol. 7, No. 1 ( 2021-01)
    Abstract: We recently discovered a short synthetic peptide derived from the ANA/BTG3 protein Box A region called ANA‐TA9 (SKGQAYRMI), which possesses catalytic activity. Herein we demonstrated the proteolytic activity of ANA‐TA9 against amyloid beta 42 (Aβ42). Methods The proteolytic activity of ANA‐TA9 against both the authentic soluble form Aβ42 ( a ‐Aβ42) and the solid insoluble form Aβ42 ( s ‐Aβ42) was analyzed by high‐performance liquid chromatography and mass spectrometry. Plasma clearance, brain uptake, and cell viability were examined. Results ANA‐TA9 cleaved not only a ‐Aβ42 but also s ‐Aβ42. Proteolytic activity was partially inhibited by 4‐(2‐aminoethyl) benzenesulfonyl fluoride hydrochloride, a serine protease inhibitor. Plasma clearance was very rapid, and the brain concentration indicated efficient brain delivery of ANA‐TA9 via nasal application. Cell viability analysis indicated that ANA‐TA9 did not display toxicity. Discussion ANA‐TA9 is an attractive potential candidate for the development of novel peptide drugs in Alzheimer's disease treatment.
    Type of Medium: Online Resource
    ISSN: 2352-8737 , 2352-8737
    URL: Issue
    URL: Article
    DOI: 10.1002/trc2.v7.1
    DOI: 10.1002/trc2.12146
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 2832891-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Sunitinib decreases the expression of KRT6A and SERPINB1 in 3D human epidermal models
    Wiley ; 2021
    In:  Experimental Dermatology Vol. 30, No. 3 ( 2021-03), p. 337-346
    Details
    In: Experimental Dermatology, Wiley, Vol. 30, No. 3 ( 2021-03), p. 337-346
    Abstract: Hand–foot skin reaction (HFSR) is a common side effect caused by several tyrosine kinase inhibitors, including sunitinib. However, the nature of the cornifying factors related to the molecular biological mechanisms underlying HFSR remains poorly understood. We used human keratinocyte models to investigate the key cornifying factors for dermatological and biological abnormalities induced by sunitinib. On the basis of the results of microarray analysis using the three‐dimensional (3D) human epidermal model, keratin (KRT)6A, serine protease inhibitor (SERPIN)B1, KRT5, and SERPIN Kazal‐type 6 were selected as candidate genes related to HFSR. Sunitinib treatment significantly decreased the expression of SERPINB1 and KRT6A in the immunohistochemical staining of the 3D epidermal model. In PSVK1 cells, but not in normal human epidermal keratinocyte cells, both of which are human normal keratinocyte cell lines, sunitinib decreased the expression of KRT6A with a concomitant decrease in levels of phosphorylated extracellular signal‐regulated kinases (ERK)1/2 and phosphorylated p38 mitogen‐activated protein kinase (MAPK). Inhibitors of the ERK and p38 MAPK signal pathways also significantly decreased KRT6A expression. Sunitinib‐induced decrease in KRT6A expression was suppressed by the inhibition of glycogen synthase kinase‐3β by enhancing ERK1/2 and p38 MAPK phosphorylation. Thus, sunitinib reduces the expression of KRT6A and SERPINB1 by inhibiting the ERK1/2 and p38 MAPK signalling pathways in the skin model. These changes in expression contribute to the pathology of HFSR.
    Type of Medium: Online Resource
    ISSN: 0906-6705 , 1600-0625
    URL: Issue
    URL: Article
    DOI: 10.1111/exd.v30.3
    DOI: 10.1111/exd.14230
    RVK:
    XA 42446
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 2026228-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...